WS
CLDX icon

Wedbush Securities’s Celldex Therapeutics CLDX Stock Holding History

Wedbush Securities’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-13,356
Closed -$36K – 986
2019
Q2 		$36K Buy
+13,356
New +$45.4K ﹤0.01% 959

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wedbush Securities's CLDX Position: Q3 2019 in Review

Wedbush Securities sold out of Celldex Therapeutics (CLDX) in Q3 2019, closing a stake of 13,356 shares — an estimated $36K sold.

Wedbush Securities first reported a position in CLDX in Q2 2019 and held it in 1 quarter. The position peaked at $36K in Q2 2019. 54 funds tracked by Wall St. Rank hold CLDX as of Q3 2019.

  • Wedbush Securities reported no remaining Celldex Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Wedbush Securities sold 13,356 Celldex Therapeutics shares in Q3 2019, an estimated $36K.
  • Wedbush Securities first reported a position in Celldex Therapeutics in Q2 2019 and held it in 1 quarter.
  • Wedbush Securities's Celldex Therapeutics position peaked at $36K in Q2 2019.
  • 54 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2019.

Based on Wedbush Securities's 13F filing for Q3 2019, filed 17 Oct 2019.